Claims
- 1. A pharmaceutical composition to inhibit H-2 histamine receptors comprising a pharmaceutical carrier and in an effective amount to inhibit said receptors a heterocyclic compound of the formula: ##STR28## wherein A is such that there is formed together with the carbon atom shown an unsaturated heterocyclic nucleus, said unsaturated heterocyclic nucleus being a triazole ring; X.sub.1 is hydrogen, lower alkyl, hydroxyl, trifluoromethyl, benzyl, halogen, amino or ##STR29## X.sub.2 is hydrogen or when X.sub.1 is lower alkyl, lower alkyl or halogen, k is 0 to 2 and m is 2 or 3, provided that the sum of k and m is 3 or 4; Y is oxygen, sulphur or NH; E is oxygen or sulphur; and R.sub.1 is hydrogen, lower alkyl, benzoyl or di-lower alkylamino-lower alkyl or a pharmaceutically acceptable addition salt thereof.
- 2. A pharmaceutical composition of claim 1 in which the heterocyclic compound is N-methyl-N'-[2-(3-(1,2,4-triazolyl)methylthio)ethyl]thiourea.
- 3. A pharmaceutical composition of claim 1 in which the heterocyclic compound is N-methyl-N'-[2-(4-methyl-3-(1,2,4-triazolyl)methylthio)ethyl]thiourea.
- 4. A method of inhibiting H-2 histamine receptors which comprises administering to an animal in need of inhibition of said receptors in an effective amount to inhibit said receptors a heterocyclic compound of the formula: ##STR30## wherein A is such that there is formed together with the carbon atom shown an unsaturated heterocyclic nucleus, said unsaturated heterocyclic nucleus being a triazole or benzimidazole ring; X.sub.1 is hydrogen, lower alkyl, hydroxyl, trifluoromethyl, benzyl, halogen, amino or ##STR31## X.sub.2 is hydrogen or when X.sub.1 is lower alkyl, lower alkyl or halogen, k is 0 to 2 and m is 2 or 3, provided that the sum of k and m is 3 or 4; Y is oxygen, sulphur or NH; E is oxygen or sulphur; and R.sub.1 is hydrogen, lower alkyl, benzoyl or di-lower alkylamino-lower alkyl or a pharmaceutically acceptable addition salt thereof.
- 5. A pharmaceutical composition of claim 1 in which the pharmaceutical composition is in the form of a tablet or capsule.
- 6. A pharmaceutical composition of claim 1 in which the heterocyclic compound is present in an amount of from about 50 mg. to about 250 mg.
- 7. A method of claim 4 in which the heterocyclic compound is N-methyl-N'-[2-(3-(1,2,4-triazolyl)methylthio)ethyl]thiourea.
- 8. A method of claim 4 in which the heterocyclic compound is N-methyl-N'-[2-(4-methyl-3-(1,2,4-triazolyl)-methylthio)ethyl]thiourea.
- 9. A method of claim 4 in which the heterocyclic compound is N-methyl-N'-[2-(2-benzimidazolylmethylthio)ethyl]-thiourea.
- 10. A method of claim 4 in which the heterocyclic compound is administered orally.
- 11. A method of claim 4 in which the heterocyclic compound is administered in a daily dosage regimen of from about 150 mg. to about 1000 mg.
- 12. A method of inhibiting gastric acid secretion which comprises administering to an animal in need thereof in an effective amount to inhibit gastric acid secretion a heterocyclic compound of the formula: ##STR32## wherein A is such that there is formed together with the carbon atom shown an unsaturated heterocyclic nucleus, said unsaturated heterocyclic nucleus being a triazole or benzimidazole ring; X.sub.1 is hydrogen, lower alkyl, hydroxyl, trifluoromethyl, benzyl halogen, amino or ##STR33## X.sub.2 is hydrogen or when X.sub.1 is lower alkyl, lower alkyl or halogen; k is 0 to 2 and m is 2 or 3, provided that the sum of k and m is 3 or 4; Y ix oxygen, sulphur or NH; E is oxygen or sulphur; and R.sub.1 is hydrogen, lower alkyl, benzoyl or di-lower alkylamino-lower alkyl or a pharmaceutically acceptable addition salt thereof.
Priority Claims (4)
Number |
Date |
Country |
Kind |
6352/71 |
Mar 1971 |
GBX |
|
34334/71 |
Jul 1971 |
GBX |
|
37015/72 |
Aug 1972 |
GBX |
|
136/72 |
Feb 1972 |
IEX |
|
Parent Case Info
This is a division of application Ser. No. 837,961 filed Sept. 29, 1977, now U.S. Pat. No. 4,151,288 which is a division of application Ser. No. 758,291 filed Jan. 5, 1977, now U.S. Pat. No. 4,069,327, which is a division of application Ser. No. 637,494 filed Dec. 4, 1975, now U.S. Pat. No. 4,018,931, which is a division of application Ser. No. 451,333 filed Mar. 14, 1974, now U.S. Pat. No. 3,950,353, which is a continuation-in-part of Ser. No. 290,584 filed Sept. 20, 1972, now abandoned, which is a continuation-in-part of Ser. No. 230,451 filed Feb. 29, 1972, now abandoned.
US Referenced Citations (6)
Number |
Name |
Date |
Kind |
3718662 |
Narayaran et al. |
Feb 1973 |
|
3736331 |
Durant et al. |
May 1973 |
|
3808336 |
Durant et al. |
Apr 1974 |
|
3908014 |
Durant et al. |
Sep 1975 |
|
3950333 |
Durant et al. |
Apr 1976 |
|
3950353 |
Durant et al. |
Apr 1978 |
|
Divisions (4)
|
Number |
Date |
Country |
Parent |
837961 |
Sep 1977 |
|
Parent |
758291 |
Jan 1977 |
|
Parent |
637494 |
Dec 1975 |
|
Parent |
451333 |
Mar 1974 |
|
Continuation in Parts (2)
|
Number |
Date |
Country |
Parent |
290584 |
Sep 1972 |
|
Parent |
230451 |
Feb 1972 |
|